Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects.
about
Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsRadioimmunotherapy of human tumoursNovel CD20 monoclonal antibodies for lymphoma therapyLow-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia.Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.Novel targeted therapies for mantle cell lymphomaTreatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Monoclonal antibodies in oncology therapeutics: present and future indications.The problem of choice: current biologic agents and future prospects in RA.Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.Achieving incompatible transplantation through desensitization: current perspectives and future directions.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.Emerging immunological drugs for chronic lymphocytic leukemia.Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy ResponseCombination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Obinutuzumab for chronic lymphocytic leukemia.
P2860
Q26830569-C244E925-7B9A-4F8A-806A-CA012B18369CQ28088825-06657542-A1EF-43BC-B961-25A27DCEA13BQ28390112-075C8D48-C9FD-49B9-975B-3BDFCD9BB248Q33408915-2C834672-BBD6-48E1-98FC-ECA23D3F65C7Q33434522-E4E76742-18FF-459B-840A-E1EAB45C355BQ34440110-6444EC34-0844-42DC-946E-91117EE0F3B8Q34463593-08FB5F6E-CC7A-43C8-A295-D64AD8271DEDQ34750560-D2BF2571-B63C-4ED6-B0EF-65AC8852083BQ35170984-1141F22B-7F73-402F-BA2E-1D327AE6531EQ35889841-A4BE0F7C-DAE8-4F5F-BA8B-A13A72403819Q37178611-FBA11768-0F9D-4013-9257-14C885A48133Q37810901-AA98770E-F6FC-40BD-96C3-81812006F9BCQ38068494-55EA5C1F-E53C-4C45-9E46-62C60CC9DEE1Q38071374-ECE0932D-A262-4593-9134-772A083F9A90Q38082588-BAB059A7-60B7-42CA-AE4B-45B6AD1799F7Q38087506-F033E4E5-1DBF-4BE0-8CF1-E708BED97D43Q38445336-9BBF5C78-2D91-443C-9EA8-78E043D35BE0Q38530254-BBC1555D-8F79-4279-AB1C-2E09B940FE5FQ38543771-6D3CAFCC-C181-4513-BE02-CAF5BD98DCC9Q38573785-A90D13E1-D1D4-4049-A994-F8F5BBAAAAF9Q38896113-AA669505-E4DF-46CB-BC73-79B89B3F3B3BQ39564060-1DD25A28-0AE1-4EAF-AC68-9027AFE013DBQ40519355-8226BA23-E60D-4044-BB5B-A7488109E31DQ47221234-CCFD265B-E7DB-4483-8FD1-9B91408DB55CQ53463137-ED32871A-9100-485F-A74C-C2975A7BF983
P2860
Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Veltuzumab (humanized anti-CD2 ...... results, and future prospects.
@ast
Veltuzumab (humanized anti-CD2 ...... results, and future prospects.
@en
type
label
Veltuzumab (humanized anti-CD2 ...... results, and future prospects.
@ast
Veltuzumab (humanized anti-CD2 ...... results, and future prospects.
@en
prefLabel
Veltuzumab (humanized anti-CD2 ...... results, and future prospects.
@ast
Veltuzumab (humanized anti-CD2 ...... results, and future prospects.
@en
P2093
P2860
P1433
P1476
Veltuzumab (humanized anti-CD2 ...... results, and future prospects.
@en
P2093
David M Goldenberg
Franck Morschhauser
William A Wegener
P2860
P304
P356
10.3109/10428191003672123
P577
2010-05-01T00:00:00Z